Use of serum squamous cell carcinoma antigen assays in chemotherapy treatment of cervical cancer

Ngan, Hextan Y.S.; Wong, LC; Chan, S.Y.W.; Ma, Hansen

doi:10.1016/0020-7292(90)90993-u

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An overall accordance of 84% was reported in 49 patients [47]. In patients who receive chemotherapy as a second line treatment after radiotherapy the course of SCC antigen reflects the clinical response in 87-100% of the cases [33,39,42]. However, the sensitivity of SCC antigen measurements to detect small tumor volumes remains to be established.…”

Section: Prognosismentioning

confidence: 66%

“…However, the sensitivity of SCC antigen measurements to detect small tumor volumes remains to be established. Normal SCC antigen levels may not indicate complete eradication of tumor [39]. Normalized SCC antigen levels correlate with a clinical response to radio-or chemotherapy, but the rate of normalization, as calculated by logistic regression, did not help to identify responders [51].…”

Section: Prognosismentioning

confidence: 99%

“…An ineffective regimen should be stopped or changed to avoid unnecessary suffering from side effects. In patients with metastatic disease the clinically apparent tumor may represent only a part of the total tumor burden and serum SCC antigen may better reflect the total tumor burden [39]. In cervical cancer patients who received chemotherapy as their primary treatment, or as an initial treatment before radiotherapy, serial SCC measurements indicated a response by decreasing levels in 91% of the cases [50].…”

Section: Prognosismentioning

confidence: 99%

See 2 more Smart Citations

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

et al. 1998

View full text Add to dashboard Cite

A review is given of the clinical use and interpretation of serum tumor marker levels during the treatment of patients with cancer of the uterine cervix. Pretreatment serum squamous cell carcinoma (SCC) antigen provides a new prognostic factor in early stage squamous cell carcinoma of the uterine cervix. Elevated serum values of SCC antigen at the time of diagnosis of stage IB and IIA cervical cancer indicate a 3 × increased risk of tumor recurrence, independent of tumor diameter, grade or the presence of lymph node metastases. High pretreatment SCC antigen levels could therefore be used to select ‘high-risk’ patients for adjuvant therapy. Measurement of the serum SCC antigen levels provides a means of monitoring the effect of therapy. During the postoperative follow-up of patients with localized cancer of the uterine cervix the measurement of SCC antigen can lead to the early detection of recurrent disease when curative therapy is still an option. The profile of serum SCC antigen parallels the response to radiotherapy and provides a way of evaluating the effectiveness of chemotherapy. Serial measurements after surgery and during radio- and chemotherapy demonstrate that SCC antigen is a more sensitive marker for recognizing tumor progression or recurrence than CYFRA-21.1, TPS or CEA. When following up patients with a pure adenocarcinoma of the cervix measurements of serum CA 125 and CEA are preferred over SCC antigen measurements.

show abstract

Section: Prognosismentioning

confidence: 66%

Section: Prognosismentioning

confidence: 99%

Section: Prognosismentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

et al. 1998

View full text Add to dashboard Cite

show abstract

“…SCC antigen has been widely studied since that time and is presently the most reliable marker for squa mous cell cancer of the uterine cervix. Several authors report that pretreatment serum levels of SCC antigen rise with the advance of stage and with recurrence, and are correlated with the course of the disease [2,[4][5][6], Recent immunohistochemical studies have demon strated the expression of cytokeratin 19 in the normal squamous epithelium as well as in squamous cell carcino ma of the uterine cervix [8,9], Although cytokeratin 19 is a part of the cytoskeleton, some fragments may be released into the serum as a result of cell lysis or tumor necrosis, which suports the present findings indicating the utility of the cytokeratin 19 fragment as a marker of squa mous cell cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Serum Levels of Cytokeratin 19 Fragments in Cervical Cancer

Nasu

Etoh²,

Yoshimatsu³

et al. 1996

Gynecol Obstet Invest

View full text Add to dashboard Cite

Serum levels of a cytokeratin 19 fragment, Cyfra 21–1, were measured using an immunoradiometric assay in 33 women before initial treatment and in 8 women with recurrent tumor. The serum level of Cyfra 21–1 was significantly increased in women with tumors of advanced stage (FIGO) and those with recurrence. The incidence of positivity for Cyfra 21–1 tended to increase with tumor spread. Compared with squamous cell carcinoma (SCC) antigen, the sensitivity of Cyfra 21–1 was comparable to that of SCC antigen. The serum level of Cyfra 21–1 and that of SCC antigen showed a positive correlation. While the use of the serum Cyfra 21–1 level may be limited in cervical cancer by its relatively low sensitivity, a combination assay of Cyfra 21–1 and SCC antigen may be useful in the diagnosis and follow-up of patients with cervical squamous cell carcinoma.

show abstract

Use of serum squamous cell carcinoma antigen assays in chemotherapy treatment of cervical cancer

Cited by 2 publications

References 0 publications

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

Serum Levels of Cytokeratin 19 Fragments in Cervical Cancer

Contact Info

Product

Resources

About